Literature DB >> 20112433

Elucidating the pathways of degradation of denagliptin.

Biren K Joshi1, Beverly Ramsey, Byron Johnson, Daniel E Patterson, Jeremiah Powers, Kevin L Facchine, Martin Osterhout, Michael P Leblanc, Renetta Bryant-Mills, Royston C B Copley, Scott L Sides.   

Abstract

Stress testing or forced degradation studies of denagliptin (1) tosylate in solution and solid-state, its blends with excipients, and capsules were conducted in order to elucidate degradation pathways, aid formulation development, and generate data to support regulatory filings. In solution, denagliptin was stressed in acid, water, and base using organic cosolvents. In the solid-state, denagliptin was stressed under heat, humidity, and light. Blends of denagliptin with various excipients were stressed under heat and humidity in order to evaluate whether tablet was a viable dosage form. Capsules were stressed under heat, humidity, and light. It was found that denagliptin was stable in the solid-state, but degraded in solution, in blends with all excipients, and in capsules predominantly by cyclization to (3S,7S,8aS) amidine (2), which epimerized to (3S,7S,8aR) amidine (3). (3S,7S,8aR) amidine (3) subsequently hydrolyzed to the corresponding diketopiperazine (4). The purpose of this manuscript is to discuss the results of stress testing studies conducted during the development of denagliptin and the elucidation of its key degradation pathway. (c) 2010 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20112433     DOI: 10.1002/jps.22069

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  1 in total

1.  Stability enhancement of drug layered pellets in a fixed dose combination tablet.

Authors:  Matthew D Burke; Xiaorong He; Chris Cook; Greg A Petrov; Susan Long; Mark D Coffin
Journal:  AAPS PharmSciTech       Date:  2013-01-15       Impact factor: 3.246

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.